NCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
Clinical Trials
9 trialsNCT07348965 2026-04-02
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Guangzhou University of Traditional Chinese Medicine
Phase NA Recruiting
NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07304739 2025-12-26
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT05465343 2025-12-19
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Peking Union Medical College
Phase 2 Completed
NCT06643000 2025-03-06
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Henan Cancer Hospital
Phase NA Recruiting
NCT06483672 2024-07-03
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06319950 2024-03-20
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Phase 2 Not yet recruiting
NCT05813522 2023-04-14
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown